| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 618.90 | 699.90 |
| Pretax Income | -62.90 | -756.90 |
| Net Income | -53.80 | -733.00 |
| Diluted EPS | -0.78 | -10.78 |
- Net Income YoY
- +92.7%
Key highlights
- Revenue for the third quarter reached $618.90 million, down from $699.90 million year-over-year
- Net loss narrowed by 92.7% to $53.80 million, compared to a $733.00 million loss in Q3 2025
- Diluted loss per share improved to $0.78 from a loss of $10.78 in the previous year period
- Pretax loss improved to $62.90 million from a $756.90 million loss as impairment charges subsided
- Company accumulated deficit increased to $1,234.5 million as of the end of the quarter
How the Period Went
QuidelOrtho reported total revenue of $618.90 million for the third quarter of 2026, representing a decrease from the $699.90 million generated in the same period last year. This downward movement in revenue indicates a shift in the diagnostic testing market as demand for legacy products continues to normalize. Despite the lower top-line figure, the company saw a dramatic 92.7% improvement in its bottom line, narrowing its net loss to $53.80 million. This compares favorably to the massive $733.00 million net loss recorded in Q3 2025, which was primarily weighed down by a large goodwill impairment charge. Consequently, the diluted loss per share significantly improved to $0.78 from $10.78.
Margins and Profitability
- The pretax loss narrowed to $62.90 million, showing a sharp recovery from the $756.90 million loss in the prior year.
- Operational efficiency is a key focus as the company manages an accumulated deficit of $1,234.5 million.
- Management has provided full-year 2026 adjusted EBITDA guidance of $540 million to $545 million, according to Stock Titan.
- A restructuring plan set for implementation in November 2026 targets over $80 million in annual cost savings by 2027, as reported by Seeking Alpha.
- Operating results continue to be impacted by the ongoing integration and stabilization following major historical impairments.
Business Overview
As a prominent player in the medical devices sector, QuidelOrtho Corporation specializes in developing and manufacturing diagnostic testing technologies. The company serves a diverse range of end markets, including clinical laboratories, hospitals, and physician offices. Its product portfolio spans immunoassay, molecular testing, clinical chemistry, and transfusion medicine. Through its integrated platforms, the company provides critical data for healthcare professionals to manage infectious diseases, cardiology, and oncology. QuidelOrtho remains focused on decentralized testing solutions that bring diagnostic capabilities closer to the patient, aiming to capture long-term growth in the global healthcare diagnostics space.
Financial Context
- The company's market capitalization stands at approximately $966.23 million, reflecting its position in the healthcare diagnostics industry.
- Stock price performance has been volatile, with a 30.83% increase over the last month against a 15.98% decline over the current quarter.
- Technical indicators show a Relative Strength Index of 57.7, suggesting the stock is trading in a neutral range without being overbought or oversold.
- Annual revenue reached $2,730.2 million on a trailing twelve-month basis, maintaining a significant scale within the medical device sector.
- An upcoming executive leadership transition effective November 9, 2026, is expected to drive further strategic restructuring.
Down 27.5% since our story on 4 Nov: $14.09 when we broke it → $10.21 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $12.76 |
|---|---|
| 20 Oct | $14.21 |
| 21 Oct | $14.08 |
| 22 Oct | $13.48 |
| 23 Oct | $13.73 |
| 26 Oct | $13.77 |
| 27 Oct | $13.59 |
| 28 Oct | $14.01 |
| 29 Oct | $13.76 |
| 30 Oct | $13.25 |
| 2 Nov | $14.03 |
| 3 Nov | $14.09 |
| 4 Nov | $14.35 |
| 5 Nov | $12.84 |
| 6 Nov | $10.70 |
| 9 Nov | $12.09 |
| 10 Nov | $11.52 |
| 11 Nov | $11.91 |
| 12 Nov | $10.62 |
| 13 Nov | $10.74 |
| 16 Nov | $10.21 |
Industry Landscape
The diagnostic sector is currently experiencing a transition as respiratory testing volumes level off following the pandemic-driven surge. Peers in the medical device industry are increasingly turning to cost-rationalization and R&D in molecular diagnostics to sustain growth. Larger competitors have emphasized laboratory automation and digital informatics to increase market share in high-volume settings. QuidelOrtho's current restructuring efforts, including the pursuit of $80 million in annual savings, mirror broader industry trends of streamlining operations to combat inflationary pressures and shifting payer reimbursements. The company's performance remains tied to its ability to successfully execute this transition while maintaining its footprint in the centralized and point-of-care testing markets.
| Date | Announcement | Amount |
|---|---|---|
| 03 Nov 2026 | Q3 2026 revenueSource: quidelortho.com | $619.0 Million |
| 06 Aug 2026 | Q2 2026 revenueSource: quidelortho.com | $631.0 Million |
| 05 May 2026 | Q1 2026 revenueSource: prnewswire.com | $620.0 Million |
| 11 Feb 2026 | Q4 2025 revenueSource: repertoiremag.com | $724.0 Million |
| 05 Nov 2025 | Q3 2025 revenueSource: quidelortho.com | $700.0 Million |
| 05 Aug 2025 | Q2 2025 revenueSource: quidelortho.com | $614.0 Million |
| Share price | $14.09 |
|---|---|
| Market cap | $966M |
| Revenue (annual) | $2.7B |
| 1-month price change | +30.83% |
| Sector | HealthcareMedical Devices |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by QuidelOrtho Corporation announcing third quarter 2026 financial results.
Track QuidelOrtho Corp live
Get the next QuidelOrtho Corp SEC filing seconds after it lands.



